- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- GLENMARK PHARMA
GLENMARK PHARMA Share Price 
(GLPH)
Here is the latest stock price and chart of Glenmark Pharma. For more details, see the Glenmark Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Sep 26, 2018 10:15:00 AM | ||
|---|---|---|---|
| Price (Rs)650.00 | Open (Rs) 641.00 | High (Rs) 658.50 | Low (Rs) 641.00 |
| % Change2.23 | Volume 36,934 | Value (Rs) 24,007,100 | 52-Week H/L 711.55 / 483.60 |
| Live NSE Quotes | Sep 26, 2018 10:19:59 AM | ||
|---|---|---|---|
| Price (Rs)650.00 | Open (Rs) 640.85 | High (Rs) 659.30 | Low (Rs) 640.85 |
| % Change2.43 | Volume 632,331 | Value (Rs) 413,278,895 | 52-Week H/L 711.90 / 493.50 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 25.93 | P/E Ratio (x) 25.07 | Market Cap (Rs m) 176,332.00 | P/BV (x) 3.93 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
GLENMARK PHARMA Share Price Today:
GLENMARK PHARMA share price is up 2.2% to Rs 650.0 on the BSE. On the NSE, the GLENMARK PHARMA share price is up 2.4% to Rs 650.0. The total volume of shares traded is 0.7 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading up by 1.2%. And the benchmark S&P BSE SENSEX is at 36,681.0 (up 0.1%).
Over the last 30 days, the GLENMARK PHARMA share price is down 0.5%. And over the last one year, GLENMARK PHARMA share price is up 6.0%.
|
| |
Today's Market
Indian Indices Open Flat; Pharma Stocks Gain(09:30 am)
Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.5% while the Hang Seng is up 1%.
Related Views On News
GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)
Aug 13, 2018 | Updated on Aug 13, 2018For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)
May 31, 2018 | Updated on May 31, 2018For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)
Nov 7, 2017Poor show in the US, Latam and India hit profits during the quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My First Pharma Stock Recommendation!(The 5 Minute Wrapup)
Sep 21, 2018This company has not only created a niche in the pharma space, it has done so profitably.
Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)
Sep 21, 2018Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.
Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)
Sep 14, 2018Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.
How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)
Sep 17, 2018PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.
How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)
Sep 19, 2018PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.
MoreTRACK GLENMARK PHARMA
- Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLENMARK PHARMA
GLENMARK PHARMA 5-YR ANALYSIS
COMPARE GLENMARK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.